SMOFlipid®

soya-bean oil, medium-chain triglycerides, olive oil and fish oil

Intended for healthcare professionals in the Republic of Ireland only. This content contains promotional and brand information

SMOFlipid prescribing information is available by clicking on the link below

SMOFlipid is a lipid emulsion for parenteral nutrition with four different types of
oil: Soya-bean oil, Medium-chain triglycerides (MCT), Olive oil and Fish oil.

Should always be part of a complete parenteral nutritional (PN) treatment including amino acids and glucose. PN should be monitored and doses adjusted according to individual patient response. Please refer to the Summary of Product Characteristics before prescribing.

Please note product image is for illustrative purposes only and labelling on
actual products may appear differently.

Filename
SMOFlipid® Prescribing Information.pdf
Size
53 KB
Format
pdf
SMOFlipid® Prescribing Information

Details


Omega-3 fatty acids have proven benefits for adult hospitalised patients 1,2* Compared with standard PN†, hospitalised adults who received omega-3 fatty-acid enriched PN had a lower risk of infection, shorter ICU stay, shorter hospital stay and a lower sepsis risk:
  • 40% lower risk of infection (131 vs 215 events; RR 0.60, 95% CI 0.49-0.72; p<0.00001) - Co- primary endpoint
  • Shorter ICU stay (Mean stay length reduced by 1.95 days, 95% CI 0.42-3.49; p=0.01)
  • Shorter hospital stay (Mean stay length reduced by 2.14 days, 95% CI 1.36-2.93; p<0.00001)
  • 56% lower risk of sepsis (24 vs 54 events; RR 0.44, 95% CI 0.28-0.70; p=0.0004)
*Systematic review and meta-analysis of 49 randomised, controlled trials (3641 ICU or surgical patients. For the outcomes of: infection rate, 24 studies, n=2154, ARR = 8%; 30-day mortality, 20 studies, n=1839, ARR = 2%; sepsis, 9 studies, n=1141, ARR = 6%; LOHS, 26 studies, n- 2182; ICU stay, 10 studies, n=822)2
†non omega-3 fatty acid enriched.
ARR, Absolute Risk Reduction; CI, Confidence Interval; ICU, Intensive Care Unit; LOHS, length of hospital stay; NS, Not Significant; PN, Parenteral Nutrition; RR, Relative Risk.
1. Calder PC, et al. Lipids in the intensive care unit: Recommendations from the ESPEN Expert Group. Clinical Nutrition. 2018;37(1):1–18
2. Pradelli L, et al. w-3 fatty-acid enriched parenteral nutrition in hospitalized patients: Systematic review with meta-analysis and trial sequential analysis. Journal of Parenteral Enteral Nutrition. 2020;44(1):44-57.

  • Administered via intravenous infusion into a peripheral or central vein. See SmPC for further administration details
  • When used in neonates and children below 2 years, the solution (in bags and administration sets) should be protected from light exposure until administration is completed
  • If side effects occur (see SmPC), or triglyceride level goes above 3mmol/L during infusion, stop the infusion, or if necessary continue at a reduced dosage.

Supply of energy and essential fatty acids and omega-3 fatty acids to patients, as part of a parenteral nutrition regimen, when oral or enteral nutrition is impossible, insufficient or contraindicated.

Item descriptionItem codeUnit sizeCase qty
SMOFlipid® 20%2451091500ml10
 

 

Lipid Energy
200g/l2000Kcal/l

g/L=grams per litre 
Kcal/L=kilocalorie per litre

Four oil lipid emulsion3

• 30% soya-bean oil providing omega-6 fatty acids
• 30% medium-chain triglycerides providing rapidly available energy
• 25% olive oil providing omega-9 fatty acids
• 15% fish oil providing omega-3 fatty acids

3. SMOFLipid 200mg/ml Emulsion for Infusion Summary of Product Characteristics. Fresenius Kabi Limited.

Adverse events should be reported.
Reporting forms and information can be found at:
www.hpra.ie/homepage/about-us/report-an-issue
Adverse events should also be reported to Fresenius Kabi Limited, Cestrian Court, Eastgate Way, Manor Park, Runcorn, Cheshire, WA7 1NT Tel +44 (0)1928 533 533.

Job code: IE-SMOF-2400002

Date of preparation: November 2024